All In Biotech

Drug Trial Radar · NCT06772597

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

A Phase 2 Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Actual

Start

Mar 4, 2025

Primary completion

Nov 3, 2026

Study completion Oct 30, 2030

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.

Conditions

  • Prader-Willi Syndrome
  • Obesity
  • Hyperphagia

Interventions

  • SetmelanotideDrug

    Setmelanotide (daily subcutaneous injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events (AEs)Time frame: Baseline to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.